This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Dates for May

Updated with information on Biomimetic Therapeutics.

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for May:

April 30-May 4:
American College of Obstetrics and Gynecologists (ACOG) annual meeting. Investor focus will be on Columbia Labs (CBRX) and KV Pharmaceutical (KV-A).

May 2:
Dendreon (DNDN) first-quarter earnings.

May 3:
Vertex Pharmaceuticals (VRTX - Get Report) first-quarter earnings.
Mannkind (MNKD) presents at the Deutsche Bank healthcare investor conference.
Alimera Sciences (ALIM) presents new Iluvien diabetic macular degeneration data at Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

May 4:
Mannkind meets with FDA regarding Afrezza.

May 7:
Estimated FDA approval decision date for Merck's (MRK) hepatitis C drug boceprevir.

May 7-10:
Digestive Disease Week research meeting, including data presentation from NPS Pharmaceuticals (NPSP) and Ironwood Pharmaceuticals (IRWD).

May 9:
Avanir Pharmaceuticals (AVNR) first-quarter earnings.
Mannkind first-quarter earnings.

May 12:
FDA advisory panel convenes to review Biomimetic Therapeutics' (BMTI) Augment Bone Graft.
Lexicon Pharmaceuticals (LXRX) analyst/investor meeting.

May 18:
American Society of Clinical Oncology (ASCO) releases research abstracts for its annual meeting in June.

May 19:
FDA convenes advisory panel to review cardiovascular safety of Abbott Labs' (ABT) lipid-lowering drug Trilipix.

May 23:
FDA approval decision date for Vertex's hepatitis C drug telaprevir.
FDA approval decision date for Johnson & Johnson's (JNJ) HIV drug rilpivirine.

May 25-28:
European League Against Rheumatism (EULAR) annual meeting.

May 26:
Johnson & Johnson analyst/investors meeting.
Xoma (XOMA) shareholder meeting.

May 30:
FDA approval decision date for Optimer Pharmaceuticals' (OPTR) antibiotic fidaxomicin.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
OPTR $0.00 0.00%
AVNR $16.96 0.00%
CBRX $7.37 -1.07%
DNDN $0.06 -6.02%
NPSP $45.97 0.02%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs